EGFR and non-small cell lung carcinoma: Therefore, the purpose of this study was to determine the clinical characteristics of patients with EGFR exon 21 L858R point mutation-positive NSCLC who do not respond to EGFR-TKI therapy and the factors that predict response to EGFR-TKI therapy.